This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Stoeckli, T. C. Articles by Kuritzkes, D. R. Search for Related Content PubMed PubMed Citation Articles by Stoeckli, T. C. Articles by Kuritzkes, D. R.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, December 2002, p. 4000-4003, Vol. 46, No. 12
0066-4804/02/$04.00+0     DOI: 10.1128/AAC.46.12.4000-4003.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.

Phenotypic and Genotypic Analysis of Biologically Cloned Human Immunodeficiency Virus Type 1 Isolates from Patients Treated with Zidovudine and Lamivudine

Thomas C. Stoeckli,^1, Samantha MaWhinney,² Jonathan Uy,^1, Chengying Duan,¹ Jing Lu,¹ David Shugarts,¹ and Daniel R. Kuritzkes^1*

Division of Infectious Diseases,¹ Department of Preventive Medicine and Biometrics, University of Colorado Health Sciences Center, Denver, Colorado 80262²

Received 25 February 2002/ Returned for modification 30 May 2002/ Accepted 20 August 2002

Mutations at reverse transcriptase codons 44, 118, 207, and 208 were significantly correlated with reduced zidovudine susceptibility in biologically cloned human immunodeficiency virus type 1 (HIV-1) isolates. Sequences from the Stanford HIV RT and Protease Sequence Database showed that these mutations were more common in HIV-1 isolates from patients treated with zidovudine and lamivudine than in patients not treated with these drugs.

---

* Corresponding author. Present address: Section of Retroviral Therapeutics, Partners AIDS Research Center, Brigham and Women’s Hospital, 65 Landsdowne St., Rm. 449, Cambridge, MA 02139. Phone: (617) 768-8371. Fax: (617) 768-8738. E-mail: dkuritzkes{at}partners.org.

Present address: Buergerspital, 4500 Solothurn, Switzerland.

Present address: Division of Infectious Diseases, University of Illinois-Chicago, Chicago, IL.

---

Antimicrobial Agents and Chemotherapy, December 2002, p. 4000-4003, Vol. 46, No. 12
0066-4804/02/$04.00+0     DOI: 10.1128/AAC.46.12.4000-4003.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.

This article has been cited by other articles:

• Zelina, S., Sheen, C.-W., Radzio, J., Mellors, J. W., Sluis-Cremer, N. (2008). Mechanisms by Which the G333D Mutation in Human Immunodeficiency Virus Type 1 Reverse Transcriptase Facilitates Dual Resistance to Zidovudine and Lamivudine. Antimicrob. Agents Chemother. 52: 157-163 [Abstract] [Full Text]  
• Nebbia, G., Sabin, C. A., Dunn, D. T., Geretti, A. M., on behalf of the UK Collaborative Group on HIV Dru, (2007). Emergence of the H208Y mutation in the reverse transcriptase (RT) of HIV-1 in association with nucleoside RT inhibitor therapy. J Antimicrob Chemother 59: 1013-1016 [Abstract] [Full Text]  
• Svicher, V., Sing, T., Santoro, M. M., Forbici, F., Rodriguez-Barrios, F., Bertoli, A., Beerenwinkel, N., Bellocchi, M. C., Gago, F., d'Arminio Monforte, A., Antinori, A., Lengauer, T., Ceccherini-Silberstein, F., Perno, C. F. (2006). Involvement of Novel Human Immunodeficiency Virus Type 1 Reverse Transcriptase Mutations in the Regulation of Resistance to Nucleoside Inhibitors. J. Virol. 80: 7186-7198 [Abstract] [Full Text]  
• Girouard, M., Diallo, K., Marchand, B., McCormick, S., Gotte, M. (2003). Mutations E44D and V118I in the Reverse Transcriptase of HIV-1 Play Distinct Mechanistic Roles in Dual Resistance to AZT and 3TC. J. Biol. Chem. 278: 34403-34410 [Abstract] [Full Text]